Palvella Therapeutics (PVLA) Cash & Equivalents (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash & Equivalents data on file, last reported at $206.4 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 172.91% year-over-year to $206.4 million in Q1 2026; TTM through Mar 2026 was $206.4 million, a 172.91% increase from a year earlier, with the FY2025 full-year figure at $58.0 million, down 30.65% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $206.4 million, up from $58.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PVLA reached as high as $206.4 million in Q1 2026 and fell as low as $6.2 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $58.5 million across 5 years, with a median of $54.9 million in 2023.
• Across the five-year window, Cash & Equivalents tumbled 87.09% in 2024 and surged 1110.4% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $38.6 million in 2022, then sank by 80.98% to $7.4 million in 2023, then jumped by 1037.44% to $83.6 million in 2024, then slumped by 30.65% to $58.0 million in 2025, then soared by 255.96% to $206.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $206.4 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.